Restricted accessResearch articleFirst published online 2025-04
A Stable mRNA-Based Novel Multi-Epitope Vaccine Designs Against Infectious Heartland Virus by Integrated Immunoinformatics and Reverse Vaccinology Approaches
The Heartland virus (HRTV) is a tick-borne human pathogenic phlebovirus that primarily causes leukopenia and thrombocytopenia. It is transmitted by Amblyomma americanum type of tick, that is, notable for their aggressive biting behavior, affinity for human hosts, and high prevalence. Developing vaccines or immunizations against HRTV is gaining importance as a public-health preventive strategy. The current study was planned to prioritize a multi-epitope stable mRNA vaccine model against HRTV from lead B-cell and T-cell epitopes (with IC50 < 100 nM) of HRTV proteome following advanced immunoinformatics approaches. Model constructs were designed by linking the most potent, nonallergenic epitopes along with incorporation of human ribosomal protein adjuvant for immune response enhancement. The immunogenic potential of the coding vaccine molecule was examined via molecular docking against toll-like receptors immune receptors followed by normal mode analysis and molecular dynamics simulations-based energy minimization, molecular stability, and flexibility assessments. A robust, stable circular mRNA precursor of multi-epitopes vaccine model was designed by incorporating the Kozak consensus sequence, a start codon, and essential elements such as MHC class I trafficking domain (MITD), tPA, Goblin 5′ and 3′ Untranslated Region (UTRs), and a poly (A) tail. This strategic amalgamation ensures elevated immunogenicity and predicts a promising circular mRNA vaccine model against HRTV. The immune simulation predicted that the designed model vaccine is capable to elicit cell-mediated and humoral immune responses. The predicted circular mRNA vaccine precursor model is promising against HRTV to examine experimentally for its immunogenicity and safety features.
Get full access to this article
View all access options for this article.
References
1.
AimanS, AhmadA, KhanAA, et al.Vaccinomics-based next-generation multi-epitope chimeric vaccine models prediction against Leishmania tropica—a hierarchical subtractive proteomics and immunoinformatics approach. Front Immunol, 2023; 14:1259612; doi: 10.3389/fimmu.2023.1259612
2.
AliA, ManzoorU, AliSL, et al.Analysis of the capability of IgG antibodies and receptors with their relationships to food tolerance and autoimmune disorders. Int J Nat Med Heal, 2023a;3:25–32; doi: 10.52461/ijnms.v3i1.2455
3.
AliA, ManzoorU, AliSL, et al.Currently trending and futuristic biological modalities in the management of different types of diabetes: A comprehensive review. J Popul Ther Clin Pharmacol, 2023b;30:2948–2970; doi: 10.53555/jptcp.v30i18.3467
4.
AliA, AliSL, AlamriA, et al.Multi-epitope-based vaccine models prioritization against Astrovirus MLB1 using immunoinformatics and reverse vaccinology approaches. J Genet Eng Biotechnol, 2024a;23(1):100451; doi: 10.1016/j.jgeb.2024.100451
5.
AliA, AliSL, OmneyaA. A comprehensive methodological review of major developments in bioinformatics pipelines for transcriptomic data analysis. Nov Biomed, 2025; 13:46–60; doi: 10.22037/nbm.v13i1.45616
6.
AliM, PandeyRK, KhatoonN, et al.Exploring dengue genome to construct a multi-epitope based subunit vaccine by utilizing immunoinformatics approach to battle against dengue infection. Sci Rep, 2017; 7(1):9232; doi: 10.1038/s41598-017-09199-w
7.
AliSL, AliA, AlamriA, et al.Genomic annotation for vaccine target identification and immunoinformatics-guided multi-epitope-based vaccine design against Songling virus through screening its whole genome encoded proteins. Front Immunol, 2023c;14:1284366; doi: 10.3389/fimmu.2023.1284366
8.
AliSL, AliA, UllahW, et al.Illuminating the frontier of drug discovery: Unleashing the power of bioinformatics for unprecedented breakthroughs. Int J Mol Biotechnol Res, 2023d;1(2):1–10; doi: 10.37591/IJMBR
9.
AliSL, AliA, UllahW, et al.Promising vaccine models against astrovirus MLB2 using integrated vaccinomics and immunoinformatics approaches. Mol Syst Des Eng, 2024b;9(12):1285–1299; doi: 10.1039/d3me00192j
10.
AliSL, AliA, UllahW, et al.Exploring advanced genomic and immunoinformatics techniques for identifying drug and vaccine targets against SARS-CoV-2. J Genet Eng Biotechnol, 2024c;22(4):100439; doi: 10.1016/j.jgeb.2024.100439
11.
AtukpaME, OkekeEO, FaladeMO, et al.Genetic identification and determination of parasites (Babesia, Leptospira and Toxoplasma Gondi) in wild rats. Research Square, 2024; doi: 10.21203/rs.3.rs-3765664/v1
12.
BaiY, LiuD, HeQ, et al.Research progress on circular RNA vaccines. Front Immunol, 2022; 13:1091797; doi: 10.3389/fimmu.2022.1091797
13.
BhattacharyaM, SharmaAR, GhoshP, et al.TN strain proteome mediated therapeutic target mapping and multi-epitopic peptide-based vaccine development for Mycobacterium leprae. Infect Genet Evol, 2022; 99:105245; doi: 10.1016/j.meegid.2022.105245
14.
BiasiniM, BienertS, WaterhouseA, et al.SWISS-MODEL: Modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res, 2014; 42(Web Server issue):W252–W258; doi: 10.1093/nar/gku340
15.
BorahP, DebPK, Al-Shar’iNA, et al.Perspectives on RNA vaccine candidates for COVID-19. Front Mol Biosci, 2021; 8:635245; doi: 10.3389/fmolb.2021.635245
16.
Bosco-LauthAM, PanellaNA, RootJJ, et al.Serological investigation of heartland virus (Bunyaviridae: Phlebovirus) exposure in wild and domestic animals adjacent to human case sites in Missouri 2012–2013. Am J Trop Med Hyg, 2015; 92(6):1163–1167; doi: 10.4269/ajtmh.14-0702
17.
BourdetteDN, BourdetteDN, EdmondsE, et al.A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis. Mult Scler, 2005; 11(5):552–561; doi: 10.1191/1352458505ms1225oa
18.
BraultAC, SavageHM, DuggalNK, et al.Heartland virus epidemiology, vector association, and disease potential. Viruses, 2018; 10(9):498; doi: 10.3390/v10090498
19.
DengB, ZhouB, ZhangS, et al.Clinical features and factors associated with severity and fatality among patients with severe fever with thrombocytopenia syndrome Bunyavirus infection in Northeast China. PLoS One, 2013; 8(11):e80802; doi: 10.1371/journal.pone.0080802
20.
DasK, ChakrabortyS, HasanM, et al.In silico analysis to elect superior bacterial alkaline protease for detergent and leather industries. JBT, 2015; 5(3):685–698; doi: 10.24297/jbt.v5i3.1482
21.
DimitrovI, FlowerDR, DoytchinovaI. AllerTOP–a server for in silico prediction of allergens. BMC Bioinformatics, 2013; 14(Suppl 6):S4; doi: 10.1186/1471-2105-14-S6-S4
22.
DingF, ZhangW, WangL, et al.Epidemiologic features of severe fever with thrombocytopenia syndrome in China, 2011–2012. Clin Infect Dis, 2013; 56(11):1682–1683; doi: 10.1093/cid/cit100
23.
DoytchinovaIA, FlowerDR. VaxiJen: A server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinformatics, 2007; 8(1):4; doi: 10.1186/1471-2105-8-4
24.
FordE, AresMJr., Synthesis of circular RNA in bacteria and yeast using RNA cyclase ribozymes derived from a group I intron of phage T4. Proc Natl Acad Sci U S A, 1994; 91(8):3117–3121; doi: 10.1073/pnas.91.8.3117
25.
GaiZT, ZhangY, LiangMF, et al.Clinical progress and risk factors for death in severe fever with thrombocytopenia syndrome patients. J Infect Dis, 2012; 206(7):1095–1102; doi: 10.1093/infdis/jis472
26.
GodseyMS, SavageHM, BurkhalterKL, et al.Transmission of heartland virus (Bunyaviridae: Phlebovirus) by experimentally infected Amblyomma americanum (Acari: Ixodidae). J Med Entomol, 2016; 53(5):1226–1233; doi: 10.1093/jme/tjw080
27.
GruberAR, LorenzR, BernhartSH, et al.The Vienna RNA websuite. Nucleic Acids Res, 2008; 36(Web Server issue):W70–W74; doi: 10.1093/nar/gkn188
28.
GuptaS, KapoorP, ChaudharyK, et al.; Open Source Drug Discovery Consortium. In silico approach for predicting toxicity of peptides and proteins. PLoS One, 2013; 8(9):e73957; doi: 10.1371/journal.pone.0073957
29.
HuangY, HuangY, NiuB, et al.CD-HIT Suite: A web server for clustering and comparing biological sequences. Bioinformatics, 2010; 26(5):680–682; doi: 10.1093/bioinformatics/btq003
30.
IkaiA. Thermostability and aliphatic index of globular proteins. J Biochem, 1980; 88(6):1895–1898.
31.
KimB, HosnRR, RembaT, et al.Optimization of storage conditions for lipid nanoparticle-formulated self-replicating RNA vaccines. J Control Release, 2023; 353:241–253; doi: 10.1016/j.jconrel.2022.11.022
32.
KimKH, YiJ, KimG, et al.Severe fever with thrombocytopenia syndrome, South Korea, 2012. Emerg Infect Dis, 2013; 19(11):1892–1894; doi: 10.3201/eid1911.130792
33.
KimSC, SekhonSS, ShinWR, et al.Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency. Mol Cell Toxicol, 2022; 18(1):1–8; doi: 10.1007/s13273-021-00171-4
34.
LawrenceP, Escudero-PérezB. Henipavirus immune evasion and pathogenesis mechanisms: Lessons learnt from natural infection and animal models. Viruses, 2022; 14(5):936; doi: 10.3390/v14050936
35.
LópezJA, WeilenmanC, AudranR, et al.A synthetic malaria vaccine elicits a potent CD8(+) and CD4(+) T lymphocyte immune response in humans. Implications for vaccination strategies. Eur J Immunol, 2001; 31(7):1989–1998; doi: 10.1002/1521-4141(200107)31:7<1989::aid-immu1989>3.0.co;2-m
36.
LovellSC, DavisIW, ArendallWB3rd, et al.Structure validation by Calpha geometry: Phi,psi and Cbeta deviation. Proteins, 2003; 50(3):437–450; doi: 10.1002/prot.10286
37.
ManzoorU, AliA, AliSL, et al.Mutational screening of GDAP1 in dysphonia associated with Charcot-Marie-Tooth disease: Clinical insights and phenotypic effects. J Genet Eng Biotechnol, 2023; 21(1):119; doi: 10.1186/s43141-023-00568-9
38.
McGuffinLJ, BrysonK, JonesDT. The PSIPRED protein structure prediction server. Bioinformatics, 2000; 16(4):404–405; doi: 10.1093/bioinformatics/16.4.404
39.
McMullanLK, FolkSM, KellyAJ, et al.A new phlebovirus associated with severe febrile illness in Missouri. N Engl J Med, 2012; 367(9):834–841; doi: 10.1056/NEJMoa1203378
40.
MuehlenbachsA, FataCR, LambertAJ, et al.Heartland virus-associated death in Tennessee. Clin Infect Dis, 2014; 59(6):845–850; doi: 10.1093/cid/ciu434
41.
NezafatN, KarimiZ, EslamiM, et al.Designing an efficient multi-epitope peptide vaccine against Vibrio cholerae via combined immunoinformatics and protein interaction based approaches. Comput Biol Chem, 2016; 62:82–95; doi: 10.1016/j.compbiolchem.2016.04.006
42.
NielsenM, LundegaardC, LundO. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinformatics, 2007; 8:238; doi: 10.1186/1471-2105-8-238
43.
PastulaDM, TurabelidzeG, YatesKF, et al.; Centers for Disease Control and Prevention (CDC). Notes from the field: Heartland virus disease—United States, 2012–2013. MMWR Morb Mortal Wkly Rep, 2014; 63(12):270–271.
44.
RapinN, LundO, BernaschiM, et al.Computational immunology meets bioinformatics: The use of prediction tools for molecular binding in the simulation of the immune system. PLoS One, 2010; 5(4):e9862; doi: 10.1371/journal.pone.0009862
45.
RiemersmaKK, KomarN. Heartland virus neutralizing antibodies in vertebrate wildlife, United States, 2009–2014. Emerg Infect Dis, 2015; 21(10):1830–1833; doi: 10.3201/eid2110.150380
46.
RussellRJ, RussellRJ, KerryPS, et al.Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc Natl Acad Sci USA, 2008; 105(46):17736–17741; doi: 10.1073/pnas.0807142105
47.
SavageHM, GodseyMS, LambertA, et al.First detection of heartland virus (Bunyaviridae: Phlebovirus) from field collected arthropods. Am J Trop Med Hyg, 2013; 89(3):445–452; doi: 10.4269/ajtmh.13-0209
48.
SetteA, RappuoliR. Reverse vaccinology: Developing vaccines in the era of genomics. Immunity, 2010; 33(4):530–541; doi: 10.1016/j.immuni.2010.09.017
49.
SolankiV, TiwariV. Subtractive proteomics to identify novel drug targets and reverse vaccinology for the development of chimeric vaccine against Acinetobacter baumannii. Sci Rep, 2018; 8(1):9044; doi: 10.1038/s41598-018-26689-7
50.
Tahir Ul QamarM, ShokatZ, MuneerI, et al.Multiepitope-based subunit vaccine design and evaluation against respiratory syncytial virus using reverse vaccinology approach. Vaccines (Basel), 2020; 8(2):288; doi: 10.3390/vaccines8020288
51.
TakahashiT, MaedaK, SuzukiT, et al.The first identification and retrospective study of Severe Fever with Thrombocytopenia Syndrome in Japan. J Infect Dis, 2014; 209(6):816–827; doi: 10.1093/infdis/jit603
52.
ThompsonJM, IwasakiA. Toll-like receptors regulation of viral infection and disease. Adv Drug Deliv Rev, 2008; 60(7):786–794; doi: 10.1016/j.addr.2007.11.003
53.
WengG, WangE, WangZ, et al.HawkDock: A web server to predict and analyze the protein-protein complex based on computational docking and MM/GBSA. Nucleic Acids Res, 2019; 47(W1):W322–W330; doi: 10.1093/nar/gkz397
54.
WesselhoeftRA, KowalskiPS, AndersonDG. Engineering circular RNA for potent and stable translation in eukaryotic cells. Nat Commun, 2018; 9(1):2629; doi: 10.1038/s41467-018-05096-6
55.
WiedersteinM, SipplMJ. ProSA-web: Interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res, 2007; 35(Web Server issue):W407–W410; doi: 10.1093/nar/gkm290
56.
YanY, TaoH, HeJ, et al.The HDOCK server for integrated protein-protein docking. Nat Protoc, 2020; 15(5):1829–1852; doi: 10.1038/s41596-020-0312-x
57.
ZhuangL, AliA, YangL, et al.Leveraging computer-aided design and artificial intelligence to develop a next-generation multi-epitope tuberculosis vaccine candidate. Infect Med (Beijing), 2024a;3(4):100148; doi: 10.1016/j.imj.2024.100148
58.
ZhuangL, ZhaoY, YangL, et al.Harnessing bioinformatics for the development of a promising multi-epitope vaccine against tuberculosis: The ZL9810L vaccine. Decod Infect Transm, 2024b;2:100026; doi: 10.1016/j.dcit.2024.100026
59.
ZukerM. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res, 2003; 31(13):3406–3415; doi: 10.1093/nar/gkg595
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
